JP3946044B2 - ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質 - Google Patents

８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質 Download PDF

Info

Publication number
JP3946044B2
JP3946044B2 JP2001554420A JP2001554420A JP3946044B2 JP 3946044 B2 JP3946044 B2 JP 3946044B2 JP 2001554420 A JP2001554420 A JP 2001554420A JP 2001554420 A JP2001554420 A JP 2001554420A JP 3946044 B2 JP3946044 B2 JP 3946044B2
Authority
JP
Japan
Prior art keywords
protein
polynucleotide
cancer
antibody
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001554420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003520605A5 (enExample
JP2003520605A (ja
Inventor
アヤ ジャコボビッツ，
ダニエル イー． エイチ． アファー，
ピア エム． チャリテイド，
エラナ レビン，
スティーブ チャッペル ミッチェル，
レーン エス． ヒューバート，
Original Assignee
アジェンシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェンシス， インコーポレイテッド filed Critical アジェンシス， インコーポレイテッド
Publication of JP2003520605A publication Critical patent/JP2003520605A/ja
Publication of JP2003520605A5 publication Critical patent/JP2003520605A5/ja
Application granted granted Critical
Publication of JP3946044B2 publication Critical patent/JP3946044B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001554420A 2000-01-26 2001-01-26 ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質 Expired - Fee Related JP3946044B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17856000P 2000-01-26 2000-01-26
US60/178,560 2000-01-26
PCT/US2001/002651 WO2001055391A2 (en) 2000-01-26 2001-01-26 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006162937A Division JP5501550B2 (ja) 2000-01-26 2006-06-12 ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質

Publications (3)

Publication Number Publication Date
JP2003520605A JP2003520605A (ja) 2003-07-08
JP2003520605A5 JP2003520605A5 (enExample) 2006-07-27
JP3946044B2 true JP3946044B2 (ja) 2007-07-18

Family

ID=22653018

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001554420A Expired - Fee Related JP3946044B2 (ja) 2000-01-26 2001-01-26 ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質
JP2006162937A Expired - Fee Related JP5501550B2 (ja) 2000-01-26 2006-06-12 ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006162937A Expired - Fee Related JP5501550B2 (ja) 2000-01-26 2006-06-12 ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質

Country Status (12)

Country Link
US (3) US7510855B2 (enExample)
EP (2) EP1967586B1 (enExample)
JP (2) JP3946044B2 (enExample)
AT (2) ATE392474T1 (enExample)
AU (2) AU2001237973B2 (enExample)
CA (1) CA2398064C (enExample)
CY (1) CY1111522T1 (enExample)
DE (2) DE60133627T2 (enExample)
DK (1) DK1967586T3 (enExample)
ES (2) ES2304126T3 (enExample)
IL (2) IL150873A0 (enExample)
WO (1) WO2001055391A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006325595A (ja) * 2000-01-26 2006-12-07 Agensys Inc ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
CN104837860A (zh) * 2012-09-07 2015-08-12 新加坡科技研究局 肽及其用途
JP7824926B2 (ja) * 2020-07-14 2026-03-05 マイネオ エヌブイ 新生抗原の提示尤度を決定するための方法、システム及びコンピュータプログラム製品

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
HUP0002095A3 (en) * 1997-02-25 2002-02-28 Corixa Corp Seattle Compounds for immunotherapy of prostate cancer and methods for their use
JP2001519666A (ja) 1997-04-10 2001-10-23 ジェネティックス・インスチチュート・インコーポレーテッド 分泌発現配列タグ（ｓＥＳＴｓ）
EP1053319A2 (en) 1998-01-28 2000-11-22 Chiron Corporation Human genes and gene expression products ii
US6013450A (en) 1998-02-20 2000-01-11 Incyte Pharmaceuticals, Inc. CAF1-related protein
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
AU2001229340A1 (en) 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP1967586B1 (en) * 2000-01-26 2011-03-09 Agensys, Inc. 84P2A9: A prostate and testis specific protein highly expressed in prostate cancer
WO2001055321A2 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
EP1274714A2 (en) 2000-04-06 2003-01-15 Genetics Institute, LLC Polynucleotides encoding novel secreted proteins
CN1328147A (zh) 2000-06-12 2001-12-26 上海博德基因开发有限公司 一种新的多肽——人磷脂酶49.06和编码这种多肽的多核苷酸
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US20030165843A1 (en) 2000-07-28 2003-09-04 Avi Shoshan Oligonucleotide library for detecting RNA transcripts and splice variants that populate a transcriptome
EP1346040A2 (en) 2000-09-11 2003-09-24 Nuvelo, Inc. Novel nucleic acids and polypeptides
AU2001296235A1 (en) 2000-10-12 2002-04-22 Hyseq, Inc. Novel nucleic acids and polypeptides
US20070015148A1 (en) 2001-01-25 2007-01-18 Orr Michael S Gene expression profiles in breast tissue

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006325595A (ja) * 2000-01-26 2006-12-07 Agensys Inc ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質

Also Published As

Publication number Publication date
DE60144204D1 (de) 2011-04-21
DE60133627D1 (de) 2008-05-29
ES2304126T3 (es) 2008-09-16
US20040126862A1 (en) 2004-07-01
AU3797301A (en) 2001-08-07
ES2360155T3 (es) 2011-06-01
US8013126B2 (en) 2011-09-06
JP2003520605A (ja) 2003-07-08
CA2398064A1 (en) 2001-08-02
US20090170191A1 (en) 2009-07-02
EP1967586A1 (en) 2008-09-10
WO2001055391A3 (en) 2002-02-21
DK1967586T3 (da) 2011-06-20
US7582448B2 (en) 2009-09-01
ATE501255T1 (de) 2011-03-15
WO2001055391A2 (en) 2001-08-02
EP1250434B1 (en) 2008-04-16
IL150873A0 (en) 2003-02-12
CY1111522T1 (el) 2015-08-05
US20070054363A1 (en) 2007-03-08
IL150873A (en) 2010-02-17
EP1967586B1 (en) 2011-03-09
CA2398064C (en) 2012-12-18
AU2001237973B2 (en) 2006-09-07
EP1250434A2 (en) 2002-10-23
ATE392474T1 (de) 2008-05-15
DE60133627T2 (de) 2009-07-30
JP2006325595A (ja) 2006-12-07
US7510855B2 (en) 2009-03-31
JP5501550B2 (ja) 2014-05-21

Similar Documents

Publication Publication Date Title
JP4373637B2 (ja) ヒト前立腺癌において発現されるｃ型レクチン膜貫通抗原およびその使用
US7834156B2 (en) 125P5C8: tissue specific protein highly expressed in various cancers
US7199220B2 (en) 103P2D6: tissue specific protein highly expressed in various cancers
JP2013136574A (ja) 前立腺癌において発現される１３回膜貫通タンパク質
US8013126B2 (en) 84P2A9: a prostate and testis specific protein highly expressed in prostate cancer
US20020055478A1 (en) GTP-binding protein useful in treatment and detection of cancer
EP1257644B1 (en) 103p2d6: tissue specific protein highly expressed in various cancers
AU2001241742A1 (en) 103P2D6: tissue specific protein highly expressed in various cancers
AU2001237973A1 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
US6924358B2 (en) 121P1F1: a tissue specific protein highly expressed in various cancers
US20020150972A1 (en) 34P3D7: a tissue specific protein highly expressed in prostate cancer
AU2008202349B8 (en) 84P2A9: A prostate and testis specific protein highly expressed in prostate cancer
US20020102640A1 (en) 83P5G4: a tissue specific protein highly expressed in prostate cancer
AU2006249244B2 (en) 84P2A9: A prostate and testis specific protein highly expressed in prostate cancer

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20051213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060313

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060323

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20070205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070410

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20080229

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100420

Year of fee payment: 3

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D03

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20080617

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100420

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110420

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110420

Year of fee payment: 4

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120420

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120420

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130420

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130420

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140420

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees